CS173097B1 - - Google Patents
Info
- Publication number
- CS173097B1 CS173097B1 CS8204A CS820472A CS173097B1 CS 173097 B1 CS173097 B1 CS 173097B1 CS 8204 A CS8204 A CS 8204A CS 820472 A CS820472 A CS 820472A CS 173097 B1 CS173097 B1 CS 173097B1
- Authority
- CS
- Czechoslovakia
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CS8204A CS173097B1 (da) | 1972-12-01 | 1972-12-01 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CS8204A CS173097B1 (da) | 1972-12-01 | 1972-12-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CS173097B1 true CS173097B1 (da) | 1977-02-28 |
Family
ID=5432295
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CS8204A CS173097B1 (da) | 1972-12-01 | 1972-12-01 |
Country Status (1)
| Country | Link |
|---|---|
| CS (1) | CS173097B1 (da) |
Cited By (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7524957B2 (en) | 2001-08-17 | 2009-04-28 | Astrazeneca Ab | Compounds effecting glucokinase |
| US7642259B2 (en) | 2005-07-09 | 2010-01-05 | Astrazeneca Ab | Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes |
| US7671060B2 (en) | 2006-10-26 | 2010-03-02 | Astrazeneca Ab | Heteroaryl benzamide derivatives |
| US7696191B2 (en) | 2006-12-21 | 2010-04-13 | Astrazeneca Ab | Crystalline compound |
| US7700640B2 (en) | 2004-10-16 | 2010-04-20 | Astrazeneca Ab | Process for making phenoxy benzamide compounds |
| US7709505B2 (en) | 2002-11-19 | 2010-05-04 | Astrazeneca Ab | Benzofuran derivatives, process for their preparation and intermediates thereof |
| US7745475B2 (en) | 2004-06-05 | 2010-06-29 | Astrazeneca Ab | Heteroaryl benzamide derivatives as GLK activators |
| US7902200B2 (en) | 2006-10-23 | 2011-03-08 | Astrazeneca Ab | Chemical compounds |
| US7943607B2 (en) | 2005-05-27 | 2011-05-17 | Astrazeneca Ab | Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes |
| US7973178B2 (en) | 2005-11-28 | 2011-07-05 | Astrazeneca Ab | Chemical process for the preparation of an amido-phenoxybenzoic acid compound |
| US8071585B2 (en) | 2009-04-09 | 2011-12-06 | Astrazeneca Ab | Therapeutic agents |
| US8071608B2 (en) * | 2009-04-09 | 2011-12-06 | Astrazeneca Ab | Therapeutic agents |
| US8076481B2 (en) | 2009-02-13 | 2011-12-13 | Astrazeneca Ab | Chemical process 632 |
| US8093252B2 (en) | 2009-02-13 | 2012-01-10 | Astrazeneca Ab | Crystalline polymorphic form of glucokinase activator |
| US8143263B2 (en) | 2008-08-04 | 2012-03-27 | Astrazeneca Ab | Therapeutic agents |
-
1972
- 1972-12-01 CS CS8204A patent/CS173097B1/cs unknown
Cited By (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7951830B2 (en) | 2001-08-17 | 2011-05-31 | Astrazeneca Ab | Compounds effecting glucokinase |
| US7524957B2 (en) | 2001-08-17 | 2009-04-28 | Astrazeneca Ab | Compounds effecting glucokinase |
| US7709505B2 (en) | 2002-11-19 | 2010-05-04 | Astrazeneca Ab | Benzofuran derivatives, process for their preparation and intermediates thereof |
| US7745475B2 (en) | 2004-06-05 | 2010-06-29 | Astrazeneca Ab | Heteroaryl benzamide derivatives as GLK activators |
| US7700640B2 (en) | 2004-10-16 | 2010-04-20 | Astrazeneca Ab | Process for making phenoxy benzamide compounds |
| US7943607B2 (en) | 2005-05-27 | 2011-05-17 | Astrazeneca Ab | Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes |
| US7977328B2 (en) | 2005-07-09 | 2011-07-12 | Astrazeneca Ab | Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes |
| US7842694B2 (en) | 2005-07-09 | 2010-11-30 | Astrazeneca Ab | Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes |
| US7642263B2 (en) | 2005-07-09 | 2010-01-05 | Astrazeneca Ab | Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes |
| US7642259B2 (en) | 2005-07-09 | 2010-01-05 | Astrazeneca Ab | Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes |
| US7973178B2 (en) | 2005-11-28 | 2011-07-05 | Astrazeneca Ab | Chemical process for the preparation of an amido-phenoxybenzoic acid compound |
| US7902200B2 (en) | 2006-10-23 | 2011-03-08 | Astrazeneca Ab | Chemical compounds |
| US7964725B2 (en) | 2006-10-26 | 2011-06-21 | Astrazeneca Ab | Heteroarylbenzamide derivatives for use in the treatment of diabetes |
| US7671060B2 (en) | 2006-10-26 | 2010-03-02 | Astrazeneca Ab | Heteroaryl benzamide derivatives |
| US7696191B2 (en) | 2006-12-21 | 2010-04-13 | Astrazeneca Ab | Crystalline compound |
| US8143263B2 (en) | 2008-08-04 | 2012-03-27 | Astrazeneca Ab | Therapeutic agents |
| US8076481B2 (en) | 2009-02-13 | 2011-12-13 | Astrazeneca Ab | Chemical process 632 |
| US8093252B2 (en) | 2009-02-13 | 2012-01-10 | Astrazeneca Ab | Crystalline polymorphic form of glucokinase activator |
| US8071585B2 (en) | 2009-04-09 | 2011-12-06 | Astrazeneca Ab | Therapeutic agents |
| US8071608B2 (en) * | 2009-04-09 | 2011-12-06 | Astrazeneca Ab | Therapeutic agents |